Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection.
Masahiro
M
Kami
Tamae
T
Hamaki
Naoko
N
Murashige
Yukiko
Y
Kishi
Eiji
E
Kusumi
Koichiro
K
Yuji
Shigesaburo
S
Miyakoshi
Jun-Ichi
J
Ueyama
Shin-Ichi
S
Morinaga
Yoshitomo
Y
Mutou
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006509:Hepatitis B / Q000150:complications*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000821:virology; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab